


## Lapatinib

<b>Cat. No.:</b>	HY-50898		
<b>CAS No.:</b>	231277-92-2		
<b>Molecular Formula:</b>	C <sub>29</sub> H <sub>26</sub> ClFN <sub>4</sub> O <sub>4</sub> S		
<b>Molecular Weight:</b>	581.06		
<b>Target:</b>	EGFR; Autophagy; Ferroptosis		
<b>Pathway:</b>	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Autophagy; Apoptosis		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 39 mg/mL (67.12 mM)  
 \* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	1.7210 mL	8.6050 mL	17.2099 mL
	5 mM	0.3442 mL	1.7210 mL	3.4420 mL
	10 mM	0.1721 mL	0.8605 mL	1.7210 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
 Solubility: ≥ 2.08 mg/mL (3.58 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
 Solubility: ≥ 2.08 mg/mL (3.58 mM); Clear solution
- Add each solvent one by one: 5% DMSO >> 95% (20% SBE-β-CD in saline)  
 Solubility: 2.5 mg/mL (4.30 mM); Suspended solution; Need ultrasonic

### BIOLOGICAL ACTIVITY

#### Description

Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC<sub>50</sub> values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

EGFR 10.2 nM (IC <sub>50</sub> , Cell Free Assay)	ErbB2 9.8 nM (IC <sub>50</sub> , Cell Free Assay)
--	--

## In Vitro

Lapatinib (GW2016; 0.03-10  $\mu\text{M}$ ; 6 hours; BT474 and HN5 cells) treatment inhibits receptor autophosphorylation of EGFR and ErbB-2 in a dose-responsive manner. Phosphorylation of serine 473 of AKT was inhibited by GW2016 in a dose-dependent manner<sup>[1]</sup>.

Lapatinib (GW2016; 72 hours; HN5, A-43, BT474, N87, and CaLu-3 cells) treatment has a selective inhibition of the proliferation of human tumor cell lines<sup>[1]</sup>.

Lapatinib (GW2016; 1-10  $\mu\text{M}$ ; 72 hours; HN5 cells) treatment results in induces G1 arrest<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### Western Blot Analysis<sup>[1]</sup>

Cell Line:	BT474 and HN5 cells
Concentration:	0.03 $\mu\text{M}$ , 0.1 $\mu\text{M}$ , 0.3 $\mu\text{M}$ , 1 $\mu\text{M}$ , 3 $\mu\text{M}$ , or 10 $\mu\text{M}$
Incubation Time:	6 hours
Result:	Inhibited receptor autophosphorylation of EGFR and ErbB-2 in a dose-responsive manner. Phosphorylation of serine 473 of AKT was also inhibited in a dose-dependent manner.

### Cell Proliferation Assay<sup>[1]</sup>

Cell Line:	HN5, A-43, BT474, N87, and CaLu-3 cells
Concentration:	
Incubation Time:	72 hours
Result:	Inhibited the growth of tumor cells overexpressing EGFR or ErbB-2.

### Cell Cycle Analysis<sup>[1]</sup>

Cell Line:	HN5 cells
Concentration:	1 $\mu\text{M}$ , or 10 $\mu\text{M}$
Incubation Time:	72 hours
Result:	Resulted in induction of G1 arrest.

## In Vivo

Lapatinib (GW2016; 30-100 mg/kg; oral administration; twice daily; for 21 days; CD-1 nude female mice) treatment inhibits tumor xenograft growth of the HN5 cells in a dose-responsive manner at 30 and 100 mg/kg, with complete inhibition of tumor growth at the higher dose<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	CD-1 nude female mice (4-6 weeks old) with HN5 cells <sup>[1]</sup>
Dosage:	30 mg/kg, 100 mg/kg
Administration:	Oral administration; twice daily; for 21 days
Result:	Inhibited tumor xenograft growth of the HN5 cells in a dose-responsive manner.

## CUSTOMER VALIDATION

- Nature. 2017 Aug 24;548(7668):471-475.

- Nat Med. 2016 Jul;22(7):723-6.
- Nat Immunol. 2018 Mar;19(3):233-245.
- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.
- Cell Syst. 2020 Nov 18;11(5):478-494.e9.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

---

[1]. Rusnak DW, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther. 2001 Dec;1(2):85-94

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

**India Contact:**

Life Technologies (India) Pvt. Ltd.

306, Aggarwal City Mall, Opposite M2K Pitampura, Delhi – 110034 (INDIA). Ph: +91-11-42208000, 42208111, 42208222, Mobile: +91-9810521400, Fax: +91-11-42208444

Email: [customerservice@lifetechindia.com](mailto:customerservice@lifetechindia.com) Website: [www.lifetechindia.com](http://www.lifetechindia.com)